

# Robbert G Van Der Most

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3863534/publications.pdf>

Version: 2024-02-01

29  
papers

2,110  
citations

361413

20  
h-index

477307

29  
g-index

33  
all docs

33  
docs citations

33  
times ranked

3061  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021, 594, 253-258.	27.8	253
2	Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2425-2430.	7.1	249
3	Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN $\gamma$ response promoting vaccine immunogenicity. <i>Npj Vaccines</i> , 2017, 2, 25.	6.0	171
4	H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses. <i>Journal of Clinical Immunology</i> , 2011, 31, 443-454.	3.8	137
5	The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. <i>Cell</i> , 2021, 184, 3915-3935.e21.	28.9	133
6	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16.	28.9	131
7	Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. <i>Vaccine</i> , 2010, 28, 849-857.	3.8	127
8	Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. <i>Frontiers in Immunology</i> , 2017, 8, 943.	4.8	111
9	Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. <i>Vaccine</i> , 2015, 33, 4025-4034.	3.8	110
10	Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27.	3.2	90
11	Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. <i>Vaccine</i> , 2019, 37, 3006-3021.	3.8	72
12	Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial. <i>Frontiers in Immunology</i> , 2017, 8, 557.	4.8	69
13	Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	56
14	Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. <i>Vaccine</i> , 2019, 37, 2004-2015.	3.8	42
15	“World in motion” emulsion adjuvants rising to meet the pandemic challenges. <i>Npj Vaccines</i> , 2021, 6, 158.	6.0	37
16	Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. <i>Npj Vaccines</i> , 2021, 6, 78.	6.0	34
17	Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in Bacillus Calmette-Guérin-Vaccinated Adults. <i>Frontiers in Immunology</i> , 2018, 9, 564.	4.8	33
18	Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	33

#	ARTICLE	IF	CITATIONS
19	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. <i>Npj Vaccines</i> , 2022, 7, .	6.0	32
20	Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1915-1922.	4.0	22
21	Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2017, 24, .	3.1	21
22	Role and plasticity of Th1 and Th17 responses in immunity to <i>Staphylococcus aureus</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2980-2992.	3.3	19
23	Seeking Help: B Cells Adapting to Flu Variability. <i>Science Translational Medicine</i> , 2014, 6, 246ps8.	12.4	18
24	Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study. <i>Journal of Infectious Diseases</i> , 2014, 210, 1419-1430.	4.0	16
25	Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. <i>Expert Review of Vaccines</i> , 2019, 18, 309-322.	4.4	15
26	Narcolepsy and A(H1N1)pdm09 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 572-576.	3.3	11
27	Evaluation of potential immunogenicity differences between <i>Pandemrix</i> and <i>Arepanrix</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2289-2298.	3.3	10
28	Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 90-102.	3.3	9
29	Comment on $\alpha$ CD4 <sup>+</sup> T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy. <i>Science Translational Medicine</i> , 2014, 6, 242le3.	12.4	1